Pfizer settles New York probe into ‘deceptive’ copay coupons By Reuters

By Jonathan Stempel

NEW YORK (Reuters) – Pfizer Inc (NYSE:) on Thursday settled charges by New York’s attorney general that it misled consumers in its drug copayment coupon program into thinking they would pay far less to fill prescriptions than they ended up having to shell out.

The drugmaker agreed to pay $500,000 in fines and costs, and make more than $200,000 in restitution over the coupons, which can help consumers burdened by health insurance plans that carry high copayments and deductibles.

Pfizer’s coupons said consumers would “PAY NO MORE THAN” $15, $20 or $25 for Estring to treat vaginal atrophy, Quillivant XR and Quillichew ER for attention deficit hyperactivity disorder, and Flector patches for acute pain from minor injuries.

New York Attorney General Barbara Underwood said this was “deceptive” because Pfizer buried limits on the total savings in the small print, and that thousands of consumers ended up paying much more.

Underwood said one woman got a surprise at her pharmacy register when she was required to pay $144.62 for Estring instead of the promised $15 maximum.

The settlement resolves claims from 2014 to 2017, and Underwood said the rate at which New York consumers paid more than the advertised maximums went up over time.

Pfizer changed the text of its coupons this year to say consumers could “pay as little as” specified amounts.

The New York-based company acknowledged some of the attorney general’s findings but did not admit or deny liability.

Pfizer confirmed the settlement, and said reimbursements will go to consumers who used coupons in the last three years.

It refunded $129.62 to the woman who paid $144.62 for Estring after the attorney general’s office intervened, according to a footnote in the settlement agreement.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.